Celgene to acquire Abraxis

LOS ANGELES Abraxis BioScience shareholders have approved an acquisition of the company by Celgene, Celgene said Wednesday.

The $3 billion acquisition will give Celgene control of Abraxis’ cancer therapies and its anti-tumor Nab technology.

“We appreciate this vote of support by Abraxis’ shareholders and look forward to bringing together the talent and resources of both organizations unified in vision, mission and values and aligned through a commitment to improving the lives of patients worldwide,” Celgene CEO Bob Hugin said in a statement.